Kamada: How CYTOGAM and the Saol Liability Stack Still Shape Cash
The main article showed that Kamada returned to growth, but this follow-up isolates the layer of cash still tied to the Saol acquisition: CYTOGAM fell 24%, GLASSIA royalties stepped down after the rate cut, and contingent consideration plus assumed liabilities still stood at $60.4 million at year-end 2025, with about $9.9 million due over the next 12 months.
What This Follow-Up Isolates
The main article already established that Kamada finished 2025 as a stronger commercial business, but with an open question around cash quality. This follow-up isolates one layer beneath that question: what happens when CYTOGAM weakens at the same time that the remaining Saol stack still demands material cash payments, while GLASSIA royalties are already moving to a lower run-rate.
That is the sharp read:
- CYTOGAM no longer carries the same contribution. Sales fell to $17.1 million from $22.5 million, a 24% decline, mainly because better access and coverage for antivirals such as letermovir and maribavir took share from the old use case.
- GLASSIA royalties no longer provide the same cushion. Royalty income fell to $15.8 million from $16.9 million even though Takeda sales increased, because the royalty rate dropped from 12% to 6% starting in August 2025. The company itself now points to roughly $10 million of royalties in 2026.
- The Saol stack is still large. Year-end contingent consideration plus assumed liabilities still totaled $60.4 million, versus $63.6 million a year earlier. That is only a 5.1% decline.
- Cash is still leaving the system. In 2025 Kamada paid $3.0 million for the third contingent-consideration milestone and another $2.9 million for assumed royalty obligations, and it expects to pay about $9.9 million more over the next 12 months.
That chart is the core of the story. It shows why "we paid" and "the burden disappeared" are not the same thing. Almost $5.9 million left in cash during 2025, but the balance only fell by about $3.2 million because remeasurement offset part of the roll-down.
CYTOGAM Weakened Just As the Cushion Around It Got Thinner
The 2021 acquisition of CYTOGAM, HEPAGAM B, VARIZIG and WINRHO SDF from Saol was meant to give Kamada a deeper U.S. commercial platform and turn it into a more integrated specialty-plasma company. That still sits at the center of the portfolio. The problem in 2025 is that the product sitting closest to a large portion of the remaining obligations no longer moved in the right direction.
CYTOGAM sales fell to $17.1 million in 2025, down from $22.5 million in 2024. The company is explicit about the reason: better coverage and market access for antivirals pushed some of the usage away from the product. That matters not only at the revenue line, but also at the level of how a recovery would have to happen. When a company loses sales because of a supply issue, the repair can be relatively fast. Here, management's response is slower by nature: market education, work with transplant experts, and new clinical data to support CYTOGAM alongside antivirals.
That is why the company's answer is a combination-use thesis rather than a replacement thesis. It is trying to defend CYTOGAM as a product that still belongs next to antivirals in high-risk populations. To support that effort, Kamada launched a post-marketing research program in 2025, and in November 2025 initiated the SHIELD study in high-risk kidney-transplant patients. This is not a quick commercial fix. It is a longer route to rebuilding the product's clinical positioning.
At the same time, the cushion outside CYTOGAM also got thinner. GLASSIA royalties from Takeda fell to $15.8 million from $16.9 million, not because Takeda sales weakened, but because the royalty rate dropped from 12% to 6% starting in August 2025. Kamada itself now frames 2026 around roughly $10 million of GLASSIA royalties. So one of the easier cash streams in the model is already moving lower right as CYTOGAM weakens.
| Line | Figure | Why it matters |
|---|---|---|
| CYTOGAM sales | $22.5 million in 2024 versus $17.1 million in 2025 | A 24% decline in the product sitting closest to the inherited royalty and milestone burden |
| GLASSIA royalties | $16.9 million in 2024 versus $15.8 million in 2025 | The cash cushion weakened despite higher Takeda sales |
| Expected GLASSIA royalties | about $10 million in 2026 | A lower near-term royalty annuity is already embedded in the outlook |
Why the Saol Stack Is Still Large, and Still Alive
Two different layers sit inside that stack.
The first layer is contingent consideration. Kamada paid $95 million upfront in 2021 and agreed to up to another $50 million subject to sales thresholds through the end of 2034. Through the end of 2025, the first three thresholds had already been achieved and paid, and the company says it expects to meet the fourth threshold during 2026.
The second layer is assumed liabilities. This is the stickier part, because it is largely tied to CYTOGAM royalties and milestones. The note lays out three royalty layers: 10% of annual global CYTOGAM net sales up to $25 million and 5% above that level, plus another 2% of annual global CYTOGAM net sales, both in perpetuity, and an additional 8% of net sales for six years starting October 1, 2023, subject to a $5 million annual cap and a $30 million aggregate cap. This is not a trivial tail from an old transaction. It is a liability layer that remains directly linked to product performance.
| Component | 2024 | 2025 | What it represents |
|---|---|---|---|
| Contingent consideration | $23.6 million | $23.2 million | Sales-threshold payments through 2034 |
| Assumed liabilities | $40.1 million | $37.2 million | Mostly CYTOGAM-linked royalties and milestones, some without a fixed end date |
| Total stack | $63.6 million | $60.4 million | Only a slow roll-down despite 2025 cash payments |
| Current maturities | $10.2 million | $9.9 million | The cash layer expected to leave over the next 12 months |
What matters here is not just the absolute size, but the speed. Kamada paid $5.9 million in cash during 2025 on contingent consideration, acquired-inventory liability and assumed liabilities, yet the remaining stack only fell by $3.2 million. That means the company has already reached the stage where a cash payment does not automatically translate into an equal decline in the outstanding burden.
Where Accounting Looks Cleaner Than the Economics
This is probably the easiest point to miss on a fast read of the filing.
Financial expense related to contingent consideration and other long-term liabilities fell to $2.7 million in 2025, versus $8.1 million in 2024. On first look, that reads like a clear improvement. But the company itself says the year-over-year change was driven by lower CYTOGAM sales, which reduced the revaluation expense.
In other words, part of the accounting relief came from operating weakness. That is not the same conclusion. When the accounting expense gets easier because the underlying product got softer, it should not be read as a clean improvement in business quality.
That also matters for how to interpret 2025 as a whole. If the reader focuses only on net income or the financing line, part of the improvement can look cleaner than it really was. The cash layer tells a tougher story: $3.0 million for the third contingent-consideration milestone was already paid in 2025, another $2.9 million was paid on assumed royalty obligations, and the company expects about $9.9 million more over the next 12 months.
What This Means for Accessible Cash
The main article already showed that Kamada is not an immediate bank-pressure story. The company ended 2025 with about $75.5 million of cash and says current resources should be sufficient for at least the next 12 months. This follow-up does not change that read. It does change a different question: how much of that cash is truly free once the Saol stack is taken into account.
Operating cash flow was $25.5 million in 2025. Within financing cash flow, $5.9 million went to Saol-related items. Over the next 12 months, the company expects about $9.9 million more of those payments. At the same time, the company now points to roughly $10 million of GLASSIA royalties in 2026.
That is not an accounting set-off. It is just a useful economic frame: one of Kamada's easier cash streams in 2026 is almost the same size as the near-term Saol payment layer. Not because the cash is legally ring-fenced one against the other, but because in practice a large part of the easy cushion can disappear before it turns into truly free cash.
That is the difference between created value and accessible value. The Saol transaction is still working in the sense that it built a deeper U.S. commercial portfolio for Kamada. But as long as CYTOGAM is weaker, as long as part of the assumed obligations remain open-ended, and as long as GLASSIA royalties are already on a lower path, the cash balance should not be read as being as free as it looks on a first pass.
Bottom Line
The central point of this follow-up is straightforward: the Saol deal has not yet fully moved from value creation to value release. In 2025, CYTOGAM weakened by 24%, GLASSIA royalties moved to a lower run-rate, and contingent consideration plus assumed liabilities still sat at $60.4 million, with about $9.9 million due over the next 12 months.
That does not mean the transaction failed. It also does not mean Kamada is under balance-sheet stress. It does mean the market should read 2026 less through the question of whether the company is still growing, and more through the question of who gets to keep the cash. If CYTOGAM stabilizes, if the stack starts rolling down faster than cash is being consumed, and if the rest of the portfolio starts leaving real surplus after that layer, the read on accessible value improves. Until then, part of the cash Kamada generates still stops one station earlier.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.